Domain Pharma

Domain Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology. The company utilizes its proprietary bioSens-All platform to identify and characterize GPCR-mediated signaling pathways, enabling the design of precision medicines that bypass resistance mechanisms in the tumor microenvironment. Its lead programs include inhibitors of the adenosine pathway and EP4 receptors, aimed at restoring the immune system's ability to fight cancer. With operations in France and Canada, Domain Therapeutics collaborates with major pharmaceutical companies while advancing its own internal pipeline of small molecules and antibodies.